FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Drug discovery against GPCRs can be difficult because the proteins quickly fall apart when removed from their natural membrane environment. Confo Therapeutics N.V. has developed Confobodies, which mimic the role of the G protein to stabilize GPCRs in a soluble form for use in screening assays. read more
Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor. Oncurious is a new oncology company and a joint venture between ThromboGenics NV and VIB, a leading life sciences institute in Flanders (Belgium). read more
The establishment of Confo Therapeutics, a spin-off of VIB and Vrije Universiteit Brussel, was announced today. A consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI contributed € 3 million in the first institutional round of investment. These resources will be used to develop further the innovative CONFO® technology platform and initiate drug discovery programs. read more
Turnstone lanceert een nieuw online platform BioVox dat achtergrondinformatie brengt bij de laatste Belgische life sciences innovaties. BioVox is het resultaat van een samenwerking tussen Turnstone, KVCV, FlandersBio, VIB, Essenscia/Bio.be, Biowin en Janssen Pharmaceutica. Het platform brengt updates over medische doorbraken, de laatste ontwikkelingen in landbouwtoepassingen en de bio-economie. read more
Thrombogenics splitst zijn kankeronderzoek af in een apart bedrijf, Oncurious. Dat richt het samen met onderzoekscentrum VIB op. Oncurious gaat zich in een eerste fase toeleggen op de ontwikkeling van een medicijn tegen een bepaald type hersentumor bij kinderen. Een zeldzame maar zeer agressieve kanker. read more
Today Hit Discovery Constance GmbH (“HDC”), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site. read more
Today, Cryo-Save opens the doors to their state-of-the-art laboratory in Pretoria, the executive capital of South Africa. The newly built laboratory is the most modern facility of its kind in the whole of Africa, and is the largest stem cell storage facility on the continent. It replaces the Cape Town lab. Cryo-Save is the leading family stem cell bank storing more than 225,000 stem cell samples from umbilical cord blood and umbilical cord tissue. read more
Galapagos NV (Euronext: GLPG) and Cangenix Ltd announced today that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering. Cangenix's state-of-the-art technology will augment Argenta's ability to design new drugs and fill a growing client need. read more
Galapagos NV (Euronext: GLPG) announced today that the research site in Zagreb, Croatia, will form the basis of a newly created service division, called Fidelta. Next to BioFocus and Argenta, this is the third service division of Galapagos. read more
A strong investment consortium, including ex-reference shareholders from DevGen (Gimv, Madeli Participaties, Biovest), has invested in the new VIB agri-biotech spin-off “AgroSavfe”. Together with Gimv-Agri+, PMV, SOFI, QBIC and VIB, they have invested 5 million EUR in the establishment of the green biotech company that develops innovative technology for sustainable crop protection. read more